Telomir Pharmaceuticals, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TELO research report →
Range $4 – $4
Price Chart
About the company
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound.
- CEO
- Erez Aminov
- IPO
- 2024
- Employees
- 2
- HQ
- Miami, FL, US
Get TickerSpark's AI analysis on TELO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $84.94M
- P/E
- -0.82
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 8.44
- EV/EBITDA
- -13.59
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -102.69%
- ROIC
- -120.93%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-10,538,849
- Net Income
- $-10,413,205+37.0%
- EPS
- $-0.33+41.1%
- OCF Growth
- +27.3%
- FCF Growth
- +27.3%
- 52W High
- $2.09
- 52W Low
- $0.89
- 50D MA
- $1.17
- 200D MA
- $1.26
- Beta
- -0.25
- RSI (14)
- 61
- Avg Volume
- 77.14K
No earnings-call transcripts are available for TELO yet.
- Free Float
- 55.8%
- Shares Outstanding
- 68.77M
- Float Shares
- 38.35M
of shares held by institutions
27 13F filers
Buy/sell ratio 1.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Capital Management LLC | 1.61M | ▲ 618.27K |
| Vanguard Group Inc | 1.14M | ▲ 35.71K |
| Geode Capital Management, LLC | 338.88K | ▲ 89.79K |
| Blackrock, Inc. | 280.47K | ▼ 8.73K |
| Vanguard Fiduciary Trust Co | 225.30K | ▲ 89.76K |
| Northern Trust Corp | 61.53K | ▲ 19.69K |
| State Street Corp | 58.60K | 0 |
| Bank Of New York Mellon Corp | 51.45K | 0 |
| Captrust Financial Advisors | 51.19K | ▲ 51.19K |
| Advisor Group Holdings, Inc. | 41.49K | ▲ 5.70K |
| Pensionmark Financial Group, LLC | 37.04K | 0 |
| Resources Investment Advisors, LLC. | 23.00K | 0 |
Held by 25 ETFs
Biggest fund positions in TELO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 16, 26 | Whalen Matthew Pratt | other | 50,000 |
| Apr 16, 26 | MacPherson Edward Clouston | other | 50,000 |
| Apr 16, 26 | Del Giudice Matthew Paul | other | 50,000 |
| Jun 3, 26 | Mushak Andriy | other | 0 |
| May 21, 26 | Aminov Erez | other | 2,000,000 |
| May 21, 26 | Aminov Erez | other | 1,960,170 |
| May 21, 26 | Aminov Erez | sell | 1,960,170 |
| May 21, 26 | Aminov Erez | sell | 2,000,000 |
| May 21, 26 | Whalen Matthew Pratt | other | 25,000 |
| May 21, 26 | Whalen Matthew Pratt | sell | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TELO coverage
Recent articles, reports, and earnings notes.
No research on TELO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TELO report →Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
globenewswire.com · Oct 6
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing
newsfilecorp.com · Sep 29
Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)
globenewswire.com · Sep 17
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
globenewswire.com · Sep 14
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?
defenseworld.net · Aug 12
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
accessnewswire.com · Jun 15
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
accessnewswire.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.